Analysis of Management of Patients with COVID-19 in a Temporary Infectious Diseases Hospital Deployed on the Facilities of Republican TB Dispensary, the Republic of Tatarstan

COVID-19 is a viral infection and its prevalence requires investigation of different co-morbid conditions including tuberculosis, as well as operation of temporary infectious diseases hospitals (TIDH) for the treatment of COVID-19 deployed on the facilities of anti-tuberculosis institutions.

The objective: analysis of follow-up and treatment of patients with COVID-19 in the temporary infectious diseases hospitals deployed on the facilities of anti-tuberculosis institutions, and assessment of the impact of various medications and treatment methods on patient lethality including in those with co-morbid active tuberculosis.

Subjects and Methods. Data of 143 patients (39.2% men and 60.8% women) aged 31 to 93 years old were collected and systematized using the COVIZ software (developed in the Republic of Tatarstan to analyze COVID-19 patient management, C#). A positive result of polymerase chain reaction for coronavirus was found in 88.1% of patients on admission and in 89.5% of patients over the entire follow-up period. 120 (83.9%) patients recovered, and 23 (16.1%) died.

Results. Patients with different outcomes did not differ by age, sex, body mass index, and respiratory clinical manifestations. Oral anticoagulants prescribed before hospitalization, oral glucocorticosteroids prescribed on day 12 of the disease or later had a significant favorable effect on the COVID-19 outcome. Among those who received olokizumab, cure was achieved in 81.8%.

The effect of anticytokine therapy was higher among patients previously vaccinated with the anti-COVID vaccine who had no concomitant pathology. Antimicrobial therapy generally had no effect on the COVID-19 outcomes, and early administration of these drugs increased the likelihood of a lethal outcome. Among 173 tuberculosis patients who died of other causes than tuberculosis, only 5 (2.9%) died of COVID-19. Tuberculosis patients followed up in the temporary infectious diseases hospital deployed on the facilities of Republican TB Dispensary were characterized by a relatively favorable course of this viral infection. The fact that those patients had been detected in a TB hospital and their treatment had been started early provided a positive impact.

Conclusion. This study has demonstrated the potential for a rapid and appropriate public health response to emerging unpredictable infectious threats.

1. Avdeev S.N., Adamyan L.V., Alekseeva E.I. et al. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19) Versiya 13.1 [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection (COVID-19). Version 13.1]. Moscow, the Russian Ministry of Health, 09.11.2021, 235 p.

2. Vizel A.A., Abdulganieva D.I., Bayalieva A.D., Vanyushin A.A., Salakhova I.N., Vafina A.R., Kolesnikov P.E., Sushentsova E.V., Sagdieva M.K., Soboleva E.A., Vizel I.Yu. Analysis of the management of patients with new COVID-19 infection: the experience of the first 5 months. Prakticheskaya Pulmonologiya, 2020, no. 3, pp. 61-72. (In Russ.)

3. Vizel A.A., Abdulganieva D.I., Fedotov V.D. et al. The assessment of predictive significance of individual indicators in patients with COVID-19 at different stages of follow-up. Prakticheskaya Pulmonologiya, 2021, no. 2, pp. 29-41. (In Russ.) doi 10.24412/2409-6636-2021-12689.

4. Vizel L.A., Vizel A.A. Svidetelstvo o gosudarstvennoy registratsii programmy dlya EVM no. 2022617173 Rossiyskaya Federatsiya. Programma CoViz (KoViz): no. 2022616062: zayavl. 06.04.2022: opubl. 19.04.2022 [Certificate of State Registration of the Software no. 2022617173 Russian Federation. CoViz Software: no. 2022616062. Applied on 04/06/2022. Published on 04/19/2022]. EDN TQVNHU.

5. Gubenko N.V., Budko A.A., Plisyuk A.G., Orlova Ya.A. Association of general blood count indicators with the severity of COVID-19 in hospitalized patients. South Russian Journal of Therapeutic Practice, 2021, vol. 2, no. 1, pp. 90-101. (In Russ.) doi 10.21886/2712-8156-2021-2-1-90-101.

6. Ekaterincheva O.L., Malkova A.M., Karev V.E., Kudryavtsev I.V., Zinchenko Yu.S., Potepun T.B., Kudlay D.A., Starshinova A.A. Specific parameters of tuberculosis diagnostics in case of concurrent COVID-19. Journal Infektologii, 2021, vol. 13, no. 1, pp. 117-123. (In Russ.)

7. Zharkov A.V., Schukarev D.A., Popov M.V., Mochan K.N., Chernov K.E., Povaliy A.A., Tvorogov D.A., Chernova A.Yu., Zhekezny E.V. The results of the work of specialists of the temporary infectious diseases hospital when providing care at the municipal level of medical care for the population in the COVID-19 pandemic. Zdorovye – Osnova Chelovecheskogo Potentsiala: Problemy i Puti ikh Resheniya, 2020, vol. 15, no. 2, pp. 684-691. (In Russ.)

8. Zaytsev A.A. Community-acquired pneumonia: diagnosis, treatment, and vaccination opportunities in the context of the COVID-19 pandemic. Prakticheskaya Pulmonologiya, 2020, no. 1, pp. 14-20. (In Russ.)

9. Lebedeva I.B., Osintseva I.Yu., Bondarenko T.E., Pyanzova T.V., Brusina E.B.. COVID-19 in patients with tuberculosis: epidemiological and clinical features. Fundamentalnaya i Klinicheskaya Meditsina, 2021, vol. 6, no. 3, pp. 71-84. (In Russ.) https://doi.org/10.23946/2500-0764-2021-6-3-71-84.

10. Chocron R., Galand V., Cellier J. et al. Critical COVID‐19 France Investigators. Anticoagulation before hospitalization is a potential protective factor for COVID-19: Insight from a French multicenter cohort study // J. Am. Heart. Assoc. ‒ 2021. ‒ Vol. 10, № 8. ‒ P. e018624. doi: 10.1161/JAHA.120.018624.

11. Pinzón M. A., Ortiz S., Holguín H., Betancur J. F., Cardona Arango D., Laniado H., Arias Arias C., Muñoz B., Quiceno J., Jaramillo D., Ramirez Z. Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia. PLoS One // 2021. ‒ Vol. 16, № 5. ‒ P. e0252057. doi: 10.1371/journal.pone.0252057.

12. Tadolini M., Codecasa L. R., García-García J. M. et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases // Eur. Respir. J. ‒ 2020. ‒ Vol. 56, № 1. ‒ P. 2001398. doi: 10.1183/13993003.01398-2020.